InsiderTrades.com logo
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
From Paradigm Press   |   Ad
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Click here to find out that this 8,788% cryptocurrency is.

TLX Insider Trading

Insider Ownership Percentage: 25.60%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Telix Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Telix Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Telix Pharmaceuticals Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/12/2020 01:00 AM ET

This chart shows the closing price history over time for TLX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
From Traders Agency   |   Ad
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Telix Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/18/2024Christian BehrenbruchInsiderExercise153,298A$11.00A$1,686,278.00
5/30/2023Christian BehrenbruchInsiderIssued120,268A$2.97A$356,714.89
3/16/2023Tiffany OlsonInsiderBuy51,305A$6.69A$343,384.37
12/12/2022Tiffany OlsonInsiderBuy10,930A$6.70A$73,252.86
11/9/2022Jann SkinnerInsiderIssued495,000A$1.09A$539,550.00
6/3/2022Tiffany OlsonInsiderBuy33,000A$4.11A$135,663.00
4/27/2022Oliver BuckInsiderBuy250,000A$4.37A$1,092,500.00
2/3/2022Christian BehrenbruchInsiderBuy400,000A$1.09A$436,000.00
1/27/2022Christian BehrenbruchInsiderSell2,000,000A$7.70A$15,400,000.00
9/29/2021Harry McCannInsiderBuy990,000A$0.85A$841,500.00
5/12/2021Christian BehrenbruchInsiderIssued100,708A$3.71A$373,626.68
See Full Table
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
From Paradigm Press   |   Ad
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Click here to find out that this 8,788% cryptocurrency is.

SEC Filings (Institutional Ownership Changes) for Telix Pharmaceuticals (ASX:TLX)

11.14% of Telix Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Telix Pharmaceuticals logo
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Read More on Telix Pharmaceuticals

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

746,789 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.35

Who are the company insiders with the largest holdings of Telix Pharmaceuticals?

Telix Pharmaceuticals' top insider shareholders include:
  1. Christian Behrenbruch (Insider)
  2. Jann Skinner (Insider)
  3. Oliver Buck (Insider)
  4. Tiffany Olson (Insider)
Learn More about top insider investors at Telix Pharmaceuticals.
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
From Paradigm Press   |   Ad
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Click here to find out that this 8,788% cryptocurrency is.